EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
Proceeds will be used to support U.S. commercialization of Altius®, a direct electrical nerve stimulation system designed to treat chronic, intractable post-amputation pain in adult amputeesPost-amputation pain is a severely underserved indication, affecting up to 80% of amputees in the U.S., with few effective non-opioid treatment optionsView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-usd-56-million-series-d-financing-in-neuros-medical-to-commercialize-fda-approved-treatment-for-post-amputation-pain-302501202.html
en | boerse | 67946760 |
